ODA Chigusa

オダチグサ | ODA Chigusa

Affiliation and department：
Job title： Associate Professor
Research theme for competitive and other funds (12)：

2023 - 2026 免疫受容体制御による新たな急性脊髄損傷治療体系の確立
2022 - 2024 虚血再灌流後の臓器機能不全を予防する新規免疫学的アプローチの基盤開発
2019 - 2021 Proposal of a novel therapeutic concept for cerebral ischemic disease by regulation of efferocytosis
2018 - 2019 死細胞の貪食を制御する機構の解明
2016 - 2019 Elucidation of the regulatory mechanism of allergic disease via commensal microbiota and regulatory T cells

Show all

Papers (57)：

Koizumi, Hitoshi, Nakahashi-Oda, Chigusa, Lyu W, Yamashita-Kanemaru, Yumi, Tabuchi, Keiji, Shibuya, Kazuko, Shibuya, Akira. Development of monoclonal antibodies specific to either CD300AR111 or CD300AQ111 or both. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2023. 42. 5. 182-185
小泉仁志, 小田, ちぐさ, 渋谷彰. CD300a阻害による脳梗塞後の神経障害の軽減. Journal of Clinical and Experimental Medicine. 2023. 284. 11. 892-893
Miyashita, Daisuke, Inoue, Ryota, Tsuno, Takahiro, Okuyama, Tomoko, Kyohara, Mayu, Nakahashi-Oda, Chigusa, Nishiyama, Kuniyuki, Fukushima, Setsuko, Inada, Yutaro, Togashi, Yu, et al. Protective effects of S100A8 on sepsis mortality: Links to sepsis risk in obesity and diabetes. iScience. 2022. 25. 12
Nishiyama, Nanako, Nakahashi-Oda, Chigusa, Shibuya, Akira. Interferon-beta promotes the survival and function of induced regulatory T cells. Cytokine. 2022. 158
Yuta Nakazawa, Nanako Nishiyama, Hitoshi Koizumi, Kazumasa Kanemaru, Chigusa Nakahashi-Oda, Akira Shibuya. Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. eLife. 2021. 10

ｍore...

MISC (3)：

小田ちぐさ, 中橋, 田原聡子, 安居輝人, 菊谷仁, 本多伸一郎, 渋谷和子, 長田重一, 渋谷彰. 炎症/病態アポトーシス細胞と肥満細胞上のCD300aによる炎症応答の調節(Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor). 日本免疫学会総会・学術集会記録. 2011. 40. 232-232
Activating immune receptor MAIR-2 associates with DAP12 and FcRγ chain on peritoneal macrophages. Clinical immunology & allergology. 2010. 54. 2. 142-148
Activating immune receptor MAIR-2 associates with DAP12 and FcRγ chain on peritoneal macrophages. Clinical immunology & allergology. 2009. 52. 1. 26-33

Patents (13)：

ACTIVITY MODULATOR, MEDICINAL AGENT COMPRISING SAME, USE OF CD300A GENE-DEFICIENT MOUSE, AND ANTI-CD300A ANTIBODY
Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
アレルギー疾患に関する、CD300a発現細胞の活性調節剤を含有する医薬品、ならびにCD300a遺伝子欠損マウスおよびCD300a発現細胞の活性調節剤の使用
活性調節剤
活性調節剤、これを含有する医薬品、および抗CD300a抗体

ｍore...

Lectures and oral presentations (93)：

CD300a immunoreceptor exacerbates heart injury and adverse remodeling after myocardial infarction and reperfusion in mice
(第88回日本循環器学会学術集会)
CD300a immunoreceptor exacerbates acute kidney injury and fibrosis after renal ischemia and reperfusion in mice
(第52回日本免疫学会学術集会)
CD300a immunoreceptor exacerbates heart injury and adverse remodeling after myocardial infarction and reperfusion in mice
(第52回日本免疫学会学術集会)
The role of an immune-inhibitory receptor CD300a in kidney injury.
(JSICR/MMCB 2023 Joint meeting)
CD300a exacerbates heart injury and adverse remodeling after myocardial infarction.
(International Symposium on Immune Regulation)

ｍore...

Professional career (1)：

Committee career (1)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page